01 Juli 2019

Dr. Stefano Biondi Appointed Head of CMC of BioVersys

BioVersys is strengthening its executive management team with the appointment of Dr. Stefano Biondi as Head of CMC as of July 1st, 2019. He will lead...


20 Juni 2019

BioVersys announces a EUR 6.92 Million funding of its TRIC-TB project by the IMI2 JU and extends its successful collaboration with long term partners

BioVersys has been awarded EUR 6.92 Million funding for TRIC-TB from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreemen...


27 Mai 2019

BioVersys to develop BV100 in critical care indications

BioVersys AG a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resista...


08 Apr. 2019

BIOVERSYS IS FEATURED IN A FORBES FRANCE SPECIAL

BioVersys is featured in a Forbes France special presenting 10 Swiss SME's to watch. A link to the English version can be found at the bottom of th...